CD274 and non-small cell lung carcinoma: In KEYNOTE-598, adding ipilimumab to pembrolizumab in PD-L1 ≥ 50% NSCLC did not improve OS (21.4 vs. 21.9 months; HR, 1.08; 95% CI, 0.85–1.37; p = 0.74), and increased toxicity led to early trial termination for futility [35].